Home » Newsletters » BioWorld Science

BioWorld Science

March 14, 2011

View Archived Issues

Phase I/II trials assess safety and immunogenicity of HIV vaccine F4/AS01

ATX-101 potentiates activity of chemotherapy in preclinical studies by disrupting cell cycle control

Phase I data support safety and tolerability of YH-4808 in healthy subjects

Vifor reports new hepcidin antagonists for treatment of anemia

Ambit Biosciences presents new tyrosine-protein kinase inhibitors

German researchers present novel agents for HIV

PET tracer [18F]-MK-3328 shows favorable pharmacological profile and promise in Alzheimer's disease

Kyowa Hakko Kirin begins phase III pegfilgrastim study in Japan

Novel activators of the K(Ca)2.3 channel synthesized by RaQualia researchers

Jasco Pharma and North Carolina Central University form research program

AFFiRiS' AD-02 Alzheimer's disease vaccine shows potential in phase I trial

Galapagos' GLPG-0187 enters phase Ib trial in patients with solid tumors

Oxford Vaccine Group receives grant from Action Medical Research to develop meningitis vaccine

Herceptin obtains additional approval in Japan for gastric cancer overexpressing HER2

Astellas files for Japanese approval of bixalomer for hyperphosphatemia

Janssen Pharma launches Stelara in Japan for psoriasis

Almirall launches Sativex in Spain for treatment of spasticity in MS

CTI gains rights to Chroma Therapeutics' antitumor drug tosedostat in the Americas

Collaboration established for research into beta-cell regeneration in diabetes

Phase III DEFEND-1 trial in type 1 diabetes does not meet primary endpoint

BioInvent advances phase II trial of cardiovascular drug candidate BI-204

Clinical evaluation of NVP-BKM-120 for treatment of endometrial and colorectal cancer under way

Phase I/II trial to assess safety/effectiveness of TRC-105 plus sorafenib in HCC is now recruiting

Preclinical anticancer activity supports entry of OCID-4681-S-01 in phase I trial in solid tumors

MRK-560 shows preference for PS-1-containing gamma-secretases

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...